Matches in Wikidata for { <http://www.wikidata.org/entity/Q37661017> ?p ?o ?g. }
- Q37661017 description "article científic" @default.
- Q37661017 description "article scientifique" @default.
- Q37661017 description "articolo scientifico" @default.
- Q37661017 description "artigo científico" @default.
- Q37661017 description "artículu científicu espublizáu en 2005" @default.
- Q37661017 description "bilimsel makale" @default.
- Q37661017 description "scientific article published on March 2005" @default.
- Q37661017 description "vedecký článok" @default.
- Q37661017 description "vetenskaplig artikel" @default.
- Q37661017 description "videnskabelig artikel" @default.
- Q37661017 description "vědecký článek" @default.
- Q37661017 description "wetenschappelijk artikel" @default.
- Q37661017 description "wissenschaftlicher Artikel" @default.
- Q37661017 description "наукова стаття, опублікована в березні 2005" @default.
- Q37661017 description "научни чланак" @default.
- Q37661017 description "مقالة علمية نشرت في مارس 2005" @default.
- Q37661017 name "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study" @default.
- Q37661017 name "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study" @default.
- Q37661017 name "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study." @default.
- Q37661017 type Item @default.
- Q37661017 label "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study" @default.
- Q37661017 label "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study" @default.
- Q37661017 label "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study." @default.
- Q37661017 prefLabel "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study" @default.
- Q37661017 prefLabel "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study" @default.
- Q37661017 prefLabel "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study." @default.
- Q37661017 P1433 Q37661017-6EDA18EA-24BC-4A19-BA26-8FB254D0D21F @default.
- Q37661017 P1476 Q37661017-74FBC8EF-B7E4-46E1-A726-8ED7D34E3FC5 @default.
- Q37661017 P2093 Q37661017-2178C8A1-08D2-442E-9956-C3C696F1F666 @default.
- Q37661017 P2093 Q37661017-57B076C9-B9CF-4F81-A5AB-8CC571C5E048 @default.
- Q37661017 P2093 Q37661017-7BCBF8FC-C679-4766-9152-2EEF1F26EA28 @default.
- Q37661017 P2093 Q37661017-A0D7073E-57A9-416C-9168-52A6015AF249 @default.
- Q37661017 P2093 Q37661017-B9F160BF-330F-4BF7-AAB7-4F877EDEAE49 @default.
- Q37661017 P2093 Q37661017-D1475827-1098-404E-82C8-E1A63FBDFAA3 @default.
- Q37661017 P2093 Q37661017-D1D83CC2-AB65-4E9E-92F1-E61B60563135 @default.
- Q37661017 P2093 Q37661017-E1E1CD5A-4C9B-4AC0-BA42-DD22C5D26E92 @default.
- Q37661017 P2093 Q37661017-F655DC06-B293-4023-B5C5-55EE17918E95 @default.
- Q37661017 P2860 Q37661017-009BBC85-9839-44EB-AA8A-AC24CD43D074 @default.
- Q37661017 P2860 Q37661017-093AD4AB-8ED4-49FA-A750-A349196F0F93 @default.
- Q37661017 P2860 Q37661017-09501490-D963-42AD-B4FD-5A894C74A25B @default.
- Q37661017 P2860 Q37661017-1D49B9EE-DC7B-4432-94A6-A25970C4B4C8 @default.
- Q37661017 P2860 Q37661017-1E015E7D-BD2A-4663-BE55-C11B8B7F3F91 @default.
- Q37661017 P2860 Q37661017-1F3D4752-36B6-4277-B0E3-C932BF0931D9 @default.
- Q37661017 P2860 Q37661017-2D8F5847-6263-4475-A6F1-427B57EF1EC3 @default.
- Q37661017 P2860 Q37661017-3EDA50A2-5423-4A5B-B21E-622465E11B2E @default.
- Q37661017 P2860 Q37661017-47A9667E-5CF5-41A6-996C-EF6435B90B45 @default.
- Q37661017 P2860 Q37661017-4D35FE7C-BC40-4F27-A9A9-93BF2F017FA7 @default.
- Q37661017 P2860 Q37661017-574DF115-017D-4DA9-971E-D188513A4F76 @default.
- Q37661017 P2860 Q37661017-5A0DBFEF-4132-4008-BBBC-E679DDC5248A @default.
- Q37661017 P2860 Q37661017-5E9F6EDA-D0B8-4B65-AD7D-25CD40170BB3 @default.
- Q37661017 P2860 Q37661017-60B789BA-838C-441D-B31A-6E609389B56C @default.
- Q37661017 P2860 Q37661017-62BA7240-7869-4B78-9BD1-46FFD3C3528B @default.
- Q37661017 P2860 Q37661017-62BB486A-406B-41C7-BAAE-2CEAF429353D @default.
- Q37661017 P2860 Q37661017-89BCAD7B-72ED-42BF-BE9C-212A847EFF1C @default.
- Q37661017 P2860 Q37661017-938AB3B9-BD88-45DF-B52D-7C283F499443 @default.
- Q37661017 P2860 Q37661017-A0524E71-6082-4374-8291-C86ABDEA941C @default.
- Q37661017 P2860 Q37661017-A5812118-99E0-4624-AABA-27CCA9A33076 @default.
- Q37661017 P2860 Q37661017-BD9D8857-B005-48F6-B57F-3EB4F500FA72 @default.
- Q37661017 P2860 Q37661017-F7D1E9CF-FE77-4BFA-AF51-C8BAF3EBDB06 @default.
- Q37661017 P2860 Q37661017-FE671D78-93AF-4972-9130-828B74BFBFD1 @default.
- Q37661017 P304 Q37661017-565CF690-9F0B-4035-B505-F0700708DCDB @default.
- Q37661017 P31 Q37661017-9D130B68-3314-42A1-8E23-F50DE1FADBF4 @default.
- Q37661017 P356 Q37661017-D1366B8A-8515-4CCB-883D-3DC60343DFC5 @default.
- Q37661017 P433 Q37661017-BD22CD09-6FDC-40B7-B6AA-8509F77C98E4 @default.
- Q37661017 P478 Q37661017-59A69871-8A06-4F92-952C-E855EC4EC4BF @default.
- Q37661017 P50 Q37661017-996AEB10-0F9C-4405-BFE4-78D0E0E15BA5 @default.
- Q37661017 P577 Q37661017-5EE6D945-E240-4701-9F24-E7A6E772E494 @default.
- Q37661017 P5875 Q37661017-5212265E-4FAF-43AB-846D-36BECFE4A7FF @default.
- Q37661017 P698 Q37661017-C040F617-2299-4F63-AE2F-D77140BF2D41 @default.
- Q37661017 P932 Q37661017-160E94A0-A04D-43A4-A050-42C35F302765 @default.
- Q37661017 P356 J.CURTHERES.2005.04.002 @default.
- Q37661017 P698 24672118 @default.
- Q37661017 P1433 Q15752574 @default.
- Q37661017 P1476 "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study" @default.
- Q37661017 P2093 "Jesús Santos" @default.
- Q37661017 P2093 "Piedad Arazo" @default.
- Q37661017 P2093 "Rafael Torres Perea" @default.
- Q37661017 P2093 "Rainel Sánchez de la Rosa" @default.
- Q37661017 P2093 "Recover Study Group" @default.
- Q37661017 P2093 "Rosario Palacios" @default.
- Q37661017 P2093 "Santiago Echevarrfa" @default.
- Q37661017 P2093 "Santiago Moreno Guillen" @default.
- Q37661017 P2093 "Xavier Camino" @default.
- Q37661017 P2860 Q29547281 @default.
- Q37661017 P2860 Q33745859 @default.
- Q37661017 P2860 Q34071132 @default.
- Q37661017 P2860 Q34136715 @default.
- Q37661017 P2860 Q34564224 @default.
- Q37661017 P2860 Q34985833 @default.
- Q37661017 P2860 Q35125360 @default.
- Q37661017 P2860 Q35136214 @default.
- Q37661017 P2860 Q40693184 @default.
- Q37661017 P2860 Q42625324 @default.
- Q37661017 P2860 Q43613003 @default.
- Q37661017 P2860 Q44580891 @default.
- Q37661017 P2860 Q44820677 @default.
- Q37661017 P2860 Q44938310 @default.
- Q37661017 P2860 Q46127987 @default.
- Q37661017 P2860 Q47886909 @default.
- Q37661017 P2860 Q51560679 @default.